Belgium· BE-AMP-SAM504195-00

Ibrance 125 mg

A palbociclib product containing palbociclib, registered in Belgium by Pfizer Europe MA. The same ATC class is registered in 14 of our 19 countries.

ATC L01EF01

Checked against FAMHP / AFMPS (Belgium) on September 26, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about palbociclibAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Palbociclib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EF01 (palbociclib), each read from that country’s own register.

This record: Belgium, from FAMHP / AFMPS (Belgium)
8 of them publish a price we can compare per daily dose

Search palbociclib products by name

Palbociclib · ATC L01EF01

14 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of palbociclib costs, country by country.

Normalised to the WHO defined daily dose (94 mg), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Palbociclib · price per daily dose (94 mg)

USD · FX 28 Sept 2026

CH Switzerland$155.65

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)

Active substance: Palbociclib
Manufacturer: Pfizer Europe MA
Country: Belgium (BE)
ATC code: L01EF01
ATC class: Palbociclib
Defined daily dose: 94 mg, O
Reimbursed: Not published by this register
Source register: FAMHP / AFMPS (Belgium)
Last checked: September 26, 2026

Packs & prices · 3

be_apb
3523644
be_apb
7721459
be_apb
3871779

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

340 interactions on record for palbociclib.

Graded by severity as the source publishes them — 74 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check palbociclib against other medicines How interaction checks work

Palbociclib · interactions on record

340 records

74 severe
256 moderate
10 minor

Most severe, free to view

LonafarnibA16AX20severe
BerotralstatB06AC06severe
ConivaptanC03XA02severe
KetoconazoleH02CA03severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Palbociclib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All palbociclib products

Authorised across Europe · EMA

The same active substance is authorised in 16 EEA countries. Names it is sold under:

Austria · Ibrammaclib
Bulgaria · Palbociclib
Denmark · Palbociclib Newbury
Estonia · Palbociclib
Finland · Palbociclib Avansor
United Kingdom (Northern Ireland) · Palbociclib Thornton & Ross
Greece · Palbociclib Faran
Croatia · Palbociclib
Hungary · Palbociclib
Iceland · Ibrance, Palbociclib Viatris
Liechtenstein · Ibrance, Palbociclib Viatris
Malta · Palbociclib, Palbociclib Lotus
Netherlands · Ibaclib, Palbociclib Elpen
Norway · Ibrance, Palbociclib Newbury
Poland · Palbociclib Polpharma
Sweden · Brancen, Brical

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/1b73b2f0-1dbb-45e3-b555-c05e46915c9e
GET /v1/drugs/1b73b2f0-1dbb-45e3-b555-c05e46915c9e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Ibrance 125 mg",
  "name_fr": "Ibrance 125 mg",
  "name_nl": "Ibrance 125 mg",
  "amp_code": "SAM504195-00",
  "strengths": [
    "125.0000",
    "125.0000",
    "93.0000"
  ],
  "pack_count": 4,
  "substances": [
    "Palbociclib",
    "Lactose",
    "Propylene Glycol",
    "Sodium Starch Glycolate (Type A)"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Palbociclib",
  "authorisation_numbers": [
    "EU/1/16/1147/006",
    "EU/1/16/1147/005",
    "EU/1/16/1147/009"
  ]
}

API reference MCP server Plans

See everything about palbociclib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console